Novel Interleukin-Based Immunotherapy Under Study in Pancreatic Cancer – OncLive
OncLive |
Novel Interleukin-Based Immunotherapy Under Study in Pancreatic Cancer
OncLive An immunotherapy combination that adds the interleukin-10 (IL-10) agonist AM0010 to FOLFOX chemotherapy will be evaluated in a phase III trial for patients with metastatic pancreatic cancer that could introduce a new modality to the treatment paradigm … |
